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Considerable progress has been achieved in derivati-
zation of glycopeptide antibiotics by using genetic en-
gineering and in vitro enzymatic approaches. In this
issue of Chemistry & Biology, the identification and
application of a glycopeptide-specific sulfotransfer-
ase by Lamb et al. [1] expands the tool box of biocom-
binatorial synthesis.
The first generation glycopeptide antibiotics (GPAs)
vancomycin and teicoplanin (the later only approved in
Europe) have been in clinical use for several decades.
They are important drugs for the treatment of nosoco-
mial infections caused by multiresistant gram-positive
pathogens, in particular methicillin-resistant Staphylo-
coccus aureus (MRSA). The widespread use of vanco-
mycin and the fact that the resistance genes are local-
ized on transferable transposons has resulted in a
significant increase in the frequency of pathogens resis-
tant to glycopeptides [2]. As of 2002, 27.5% of nosoco-
mial infections in intensive care units in the US were
caused by vancomycin-resistant Enterococci (VRE) [3].
Moreover, the first emergence of fully vancomycin-
resistant Staphylococcus aureus (VRSA) [4] indicates
that future use of the former antibiotics ‘‘of last resort’’
is seriously threatened.
One possible way to combat these resistant bacteria
is the development of antibiotics addressing novel tar-
gets, such as linezolide or daptomycin approved in
2000 and 2003 [5]. A second successful strategy is the
semisynthetic modification of glycopeptides that led to
three second-generation glycopeptides, oritavancin, te-
lavancin, and dalbavancin, which are currently in late
clinical development (phase III) [5]. The first two agents
are derivatives of chloroeremomycin and vancomycin,
respectively, bearing N-aryl and N-alkyl lipophilic side
chains conferring novel mechanisms of action and bac-
tericidal activities against VRE [2]. Dalbavancin is an
amidated teicoplanin-like antibiotic with an improved
pharmacokinetic profile targeting the VanB, but not the
VanA, type of VRE [6]. The synthesis of second-genera-
tion glycopeptides demonstrates that GPAs displaying
improved properties can be generated by a single-step
chemical modification.
However, the broad derivatization of complex natural
products is frequently challenging using organic chem-
istry. Even though de novo synthesis of glycopeptides
could be accomplished through fascinating synthetic
chemistry, exemplified by the achievements of Nicolaou
et al. [7], economic routes to these derivatives will al-
ways rely on the biotechnological production of the pre-
cursor molecules. The past decade has witnessed major
advances in the development and application of genetic
engineering procedures as suitable alternative strate-
gies for the targeted derivatization of complex natural
products analogs. These strategies compose a panelof diverse in vivo strategies like pathway engineering,
precursor-directed biosynthesis/mutasynthesis, heter-
ologous expression and combinatorial biosynthesis
[8], and the use of naturally flexible or engineered en-
zymes for in vitro derivatization like the glycorandomiza-
tion approach [9]. While these technologies are unlikely
to compete with chemical modification approaches with
respect to the pure number of analogs produced, they
can generate a limited number of targeted and valuable
derivatives which may not be readily obtainable by or-
ganic chemistry.
The basis for applying GPA-specific bioengineering
approaches was the successful elucidation of the bio-
synthetic principles of glycopeptides. The function for
most of the individual genes involved in GPA biosynthe-
sis have been verified by two complementary strategies:
(1) analysis of accumulated intermediates in a variety
of knock out mutants, for example, in the balhimycin-
producing strain Amycolatopsis balhimycina [10, 11],
and (2) functional characterization of biosynthetic en-
zymes, for example, expression of enzymes involved in
chloroeremomycin biosynthesis in E. coli [12]. These re-
sults can be combined into a model of GPA biosynthesis
comprising the following steps: first, biosynthesis of the
unusual amino acid precursors and deoxysugars; sec-
ond, assembly of the peptide core by nonribosomal
peptide synthetases (NRPS) followed by crosslinking
oxygenations and halogenations, which most probably
occur on the growing peptide chain attached to the
nonribosomal peptide synthetases [13–15]; and third, fi-
nal decoration of the released aglycon by N-terminal
methylation, glycosylation, and in the case of type IV
GPAs, transfer of a lipid chain [2, 10].
Using this biosynthetic knowledge, several novel
GPAs have been generated by both in vivo genetic engi-
neering strategies and enzymatic in vitro biocatalysis
approaches. Targeted inactivation experiments have
produced dechloro-glycopeptides [16] and partially gly-
cosylated compounds [11]. Backbone modifications
have been achieved by precursor-directed biosynthesis
after supplementation of mutants defective in the bio-
synthesis of unusual backbone amino acids with syn-
thetic alternative precursors. These studies led to novel,
active vancomycin-like analogs such as fluorobalhimy-
cin [11, 17]. Excellent advances have been achieved in
the groups of Baltz, Kahne, and Walsh in determining
the flexibility of diverse GPA-specific glycosyltrans-
ferases that provide the basis for the in vitro enzymatic
generation of GPA analogs carrying novel sugar resi-
dues [12, 18, 19]. Due to their substrate flexibilities,
both GtfE, responsible for the transfer of a D-glucose
moiety to the vancomycin-aglycon, and GtfD, which
adds L-vancosamine to the bound glucose residue,
are versatile tools for the generation of diverse glycosy-
lated analogs, particularly after expanding the sub-
strates by using a set of diverse chemoenzymatically
synthesized NDP-sugars [12, 19].
In the study reported in this issue of Chemistry &
Biology, Lamb et al. [1] expand the options of biological
derivatization tools for GPAs by the functional
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StaL. This transferase is responsible for the sulfation of
the N-terminal amino acid, 4-hydroxyphenylglycine, of
the nonglycosylated GPA A47934. The interest in and
knowledge of eukaryotic sulfotransferases is increasing,
because these enzymes play an important role in bio-
medical and regulatory processes [20]. The function of
StaL, which is only the fourth prokaryotic sulfotransfer-
ase characterized to date, was unambiguously verified
by two strategies: (1) demonstrating that a deletion mu-
tant was able to produce only the nonsulfated com-
pound, and (2) showing that the overexpressed enzyme
displayed in vitro sulfotransferase activity using the
crosslinked nonsulfated A47934 backbone. Interest-
ingly, the substrate specificity of the sulfotransferase
was not restricted to the crosslinked A47934 backbone,
because both the teicoplanin aglycon and teicoplanin it-
self were also sulfated successfully. In contrast to the
crosslinking oxygenase and the halogenase reactions,
which take place on NRPS bound precursors [13–15],
enzymatic sulfation by StaL occurs on the free cross-
linked backbone as a final step, indicating that this en-
zyme might be applicable for other biocombinatorial ap-
proaches as well. In particular, sulfation of the important
second-generation GPA dalbavancin or its natural pre-
cursor compound A40926 seems reasonable, because
all these molecules share a conserved backbone struc-
ture [2]. Despite the fact that sulfated analogs display
a slightly decreased in vitro activity, sulfation should al-
ter the physiocochemical properties, such as charge
and solubility, of a compound. These alterations may
positively influence the in vivo efficacy of a drug,
because the in vitro activity of GPAs does not always
correspond with their in vivo efficacy. For example, non-
glycosylated glycopeptides have excellent in vitro activ-
ities, but lack in vivo efficacy [21].
The successful application of a sulfotransferase for
the generation of novel GPA derivatives expands the ex-
isting tool box for rational structural derivatization of
GPAs with biocombinatorial or enzymatic strategies.
Despite the fact that in some cases the biosynthesized
amounts of these bioengineered compounds may not
be sufficient for economic production, characterization
of the properties of such an analog, which is difficult to
obtain by chemical methods, may give valuable insights
into the potential of a valuable class of GPAs. In the fu-
ture, this knowledge may offer the opportunity to gener-
ate an optimized GPA or even a GPA precursor that in
turn can be modified by a one-step chemical derivatiza-
tion to end up with a third-generation GPA displaying
improved properties.Stefan Pelzer1 and Agnieszka Dziarnowski1
1Combinature Biopharm AG
Robert-Roessle Strasse 10
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